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1.0 Introduction 
 
 
Diabetes Mellitus (DM) is a group metabolic disorder marked by high levels of blood glucose 
resulting from defects in insulin production, insulin action or both. Prevalence of diabetes can 
vary widely depending on geography, age, sex and race. 
The incidence and prevalence of DM are increasing, with more than 135 million people 
affected worldwide. Despite greater knowledge of the disease, one-third of people with the 
disease are estimated undiagnosed (Moore et al. 2003).   
In Norway about 250.000 persons are probably affected with DM. About 25.000 individuals 
have the diagnosis of type 1 DM, while others have type 2 DM. Half of those with type 2 DM 
are still undiagnosed. 
The incidence of type 1 DM is higher in Scandinavia than Europe and the U.S.A., with more 
than 30 cases/year/100,000 people (Karvonen et al. 1993). The prevalence of DM in adults is 
slightly higher in women than men and increases significantly with age and weight. 
 As the incidence of DM is increasing worldwide, a greater number of diabetic patients will be 
seen and treated by dental practitioners. Proper dental treatment of patients with diabetes 
requires knowledge about the disease. 
 
The purpose of this project is to summarize the classification of diabetes mellitus, medical 
management, dental management of diabetics and the impact of diabetes on oral health in 
general. We are going to concentrate on the interrelationship between DM and periodontitis as 
two chronic conditions affecting each other. 
We choose to write about this field (Periodontitis and Diabetes Mellitus) because of 
increasing incidence of DM. We are trying to learn more about it as well as to present useful 
information to our colleagues.  
A better understanding of the interrelationship of diabetes and periodontitis provides more 
appropriate treatment of these patients. Dentists may detect undiagnosed cases of diabetes and 
refer patients to physicians for further evaluation.  
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2.0 Diabetes Mellitus (DM) 
DM is a group of metabolic disorders manifested by abnormally high levels of glucose in the 
blood. The hyperglycemia is the result of a deficiency of insulin secretion or insulin resistance 
or a combination of these. Insulin is required for transport of glucose from the blood stream 
into the cells, where glucose is used for energy. Deficiency of insulin secretion or insulin 
resistance results in inability to transport glucose into the cells. Glucose is thus retained in the 
blood stream, causing hyperglycemia (Mealey et al. 2004, Mealey & Ocampo 2007). 
 
2.1 Classification of Diabetes Mellitus 
Type 1 DM 
This form of DM is the result of autoimmune destruction of β-cell in pancreas, usually leading 
to total loss of insulin secretion. Type 1 DM is usually diagnosed in children and adolescents. 
In the absence of insulin these patients develop ketoacidosis, a life-threatening condition. 
Type 1 DM was previously called insulin-dependent diabetes, because type 1 patients are 
dependent on exogenous insulin for survival. 
About 85–90% of patients with type1 diabetes can have one or more of the antibodies 
associated with the autoimmune destruction. However, some type 1 diabetics have no 
evidence of autoimmunity. This form of type 1 DM is strongly inherited and known as 
idiopathic DM (Mealey & Ocampo 2007). 
In Norway about 25.000 people have the diagnosis of type 1 DM. Every year about 600 new 
cases are diagnosed to have type 1 DM, about 250 of them are children under 15 years of age. 
The number of children diagnosed to have type 1 DM is doubled during the last 30 year in 
Norway ( http://www.diabetes.no/index.asp?id=23017 ). 
Type 2 DM 
Type 2 DM is present in 90–95% of patients with the disease. Type 2 DM is characterized by 
peripheral resistance of insulin. As the condition progresses, glucose production by the liver 
increases, and insulin secretion decreases. These changes lead to sustained hyperglycemia. 
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These patients can remain undiagnosed for many years because the hyperglycemia appears 
gradually and often without symptoms. The risk of developing this form of DM increases with 
age, obesity, previous history of gestational DM and lack of physical activity (Mealey & 
Ocampo 2007). 
The highest prevalence of type 2 DM in the world is found in Pima Indians in the U.S.A. 
More than 50% of Pima Indians older than 35 years have type 2 DM. In the past 20 years, the 
incidence of type 2 DM is increased in children and teenagers. Increasing incidence of type 2 
DM among children is associated with obesity and genetics (Moore et al. 2003). 
(http://www.apotek1.no/helsesenter/diabetes/dette_er_diabetes/diabetes_type_2_). In Norway 
about 225 000 persons have type 2 DM, about half of them is undiagnosed. Every year 6000-
7000 get the diagnosis of type 2 DM. The number of patients with type 2 DM increased four 
times in the last 50 year (http://www.diabetes.no/index.asp?id=23018 ). 
Gestational Diabetes Mellitus 
Gestational diabetes mellitus is defined as glucose intolerance, which is first recognized 
during pregnancy. It only affects 1-2% of all pregnancies in Norway. Prenatal care in Norway 
is very well organized, and thus it probably reduces the risk of complications.   
(http://www.apotek1.no/helsesenter/diabetes/dette_er_diabetes/svangerskapsdiabetes) 
Gestational DM usually has its onset in the third trimester of pregnancy.  Women at high risk 
are those older than 25 years of age with positive family history of DM and obesity.  The 
increasing demand of insulin during pregnancy and hormonal changes are predisposing these 
women to the development of gestational DM (Mealey & Ocampo 2007). 
Other specific types of diabetes 
• Genetic defects of the β cell. 
• Genetic defects in insulin action. 
• Diseases of the exocrine pancreas. 
• Endocrinopathies. 
• Drug- or chemical-induced diabetes. 
• Infections. 
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• Other genetic syndromes sometimes associated with diabetes. (Mealey & Ocampo 
2007) 
 
Impaired glucose tolerance and impaired fasting glucose 
This is a condition called pre-diabetes. These individuals are normoglycemic but demonstrate 
elevated blood glucose levels after fasting and after glucose load. This condition is a strong 
predictor for future development of type 2 DM (Mealey & Ocampo 2007). 
 
2.2 Medical management of diabetes mellitus 
Treatment of DM includes not only the normalization of glycemia, but interventions to 
prevent initiation of complications or their progression. Nonpharmacological interventions are 
dietary control and exercise leading to weight loss and improvement of glycemic control. 
Dietary control that reduces carbohydrate and lipid consumption will reduce the likelihood of 
developing microvascular and macrovascular complications of DM (Robertson et al. 2003).
Pharmacological therapy 
o Insulin therapy 
Insulin therapy is indicated for all patients with type 1 DM. Insulin is also used in type 2 
diabetic patients with insulinopenia in whom diet and oral agents are inadequate to attain 
target glycemic control. Insulin therapy is also indicated for women with gestational DM who 
are not controlled with diet alone. Therapy is usually initiated with a single dose of long-
acting insulin. Multiple split-dose regimens using rapid or short-acting insulin before meals 
are then added. Insulin is usually administered as a bolus dose given subcutaneously with a 
syringe. Insulin pump or continuous subcutaneous insulin infusion therapy is another option 
for intensive insulin therapy. Insulin pumps are programmed to deliver small continuous basal 
doses of insulin throughout the day, with bolus dosing before meals (Mealey & Ocampo 
2007). 
Side-effects of insulin include increased risk of hypoglycemia. As a practical matter, 
clinicians should be aware of the time of peak insulin action for each insulin preparation 
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because the risk for peroperative hypoglycemia is usually highest at times of peak insulin 
action. 
o Oral agents 
The classes of oral hypoglycemic agents reduce plasma glucose levels by one or more 
methods: increasing insulin secretion, reducing insulin resistance or delaying glucose 
absorption by the gut (Robertson et al. 2003). 
Side-effects of oral hypoglycemic agents include weight gain and occasional hypoglycemia, 
although the risk of hypoglycemia varies, depending on the type of the oral hypoglycemic 
agent (Mealey & Ocampo 2007).  
2.3 Glycemic control: 
The best method of determining the glycemic control in a known diabetic patient is the 
Glycated Haemoglobin Assay. This test allows determination of blood glucose status over the 
30-90 days before collection of blood sample. As glucose circulates in the blood stream, it 
becomes attached to a portion of the haemoglobin molecule on red blood cells. High plasma 
glucose over time gives a higher percentage of haemoglobin that becomes glycated. The 
American Diabetes Association (2003) recommends that individuals with DM should attempt 
to achieve a target HBA1c of less than 7%, whereas an HBA1c >8% suggests that a change in 
patient management may be needed to improve glycemic control (Rees & Mealey 2004).   
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2.4 Systemic complications of diabetes mellitus 
Acute complications of diabetes mellitus 
Diabetic ketoacidosis 
Diabetic ketoacidosis is the most common life-threatening hyperglycemic emergency in 
patients with DM and it is the leading cause of death in children with type 1 DM (Charfen & 
Fernandez-Frackelton 2005). Diabetic ketoacidosis is a metabolic abnormality characterized 
by hyperglycemia and metabolic acidosis as a result of hyperketonemia with neurological 
manifestations (Kitabchi & Wall 1995). It is usually preceded by polyuria, polydipsia, 
fatigue, nausea, vomiting, and finally depression of sensorium and coma. Patients present 
themselves with one or more of the following: hyperventilation (Kussmaul breathing), signs 
of dehydration, ‘fruity’ breath odor of acetone, hypotension, tachycardia and hypothermia. 
Management includes continuous intravenous infusion of regular (short-acting) insulin 
(DeFronzo et al. 1994). Fluid replacement should be initiated as soon as possible to improve 
circulatory volume and tissue perfusion. 
 
Hyperglycemic hyperosmolar state 
Hyperglycemic hyperosmolar state is the second most common life-threatening form of 
decompensated DM (Kitabchi et al. 2001). The greatest risk is for elderly people, particularly 
those bedridden or dependent on others for their daily care. Infection is a common 
precipitating event, as is poor compliance with insulin therapy. Hyperglycemic hyperosmolar 
state is a metabolic abnormality characterized by severe hyperglycemia in the absence of 
significant ketosis, with hyperosmolarity and dehydration secondary to insulin deficiency, and 
massive glycosuria leading to excessive water loss (Ennis et al. 1994). Treatment of 
hyperglycemic hyperosmolar state consists of hydration, electrolyte replacement and small 
amounts of insulin. 
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Hypoglycemia 
Hypoglycemia is the result of excess insulin in the blood, which causes excessively low blood 
sugar levels. While symptoms vary from person to person and range in severity, there are a 
few common complaints when the blood sugar is too low. The symptoms are caused by the 
nervous system's response to low levels of circulating blood sugar. The symptoms usually 
occur gradually and may be associated with a rapid heart beat, perspiration, shakiness and 
anxiety (some of the warning signs). If these signs are ignored, and blood sugar levels 
continue to fall, more severe symptoms may occur, such as confusion, behaviour changes and 
unconsciousness. These later symptoms are the result of a reduction in fuel source to the brain. 
Eventually, a patient can develop a seizure and coma may ensure.  
  
Chronic macrovascular complications of diabetes mellitus 
Cardiovascular disease 
The risk of cardiovascular disease is markedly increased in patients with DM, and it is the 
major cause of mortality for these individuals. Several risk factors are associated with higher 
prevalence of cardiovascular disease in type 2 DM: abdominal obesity, insulin resistance, 
hypertension and dyslipidemia (Sorrentino 2005).  The prevention or slowing of 
cardiovascular disease is achieved with the intervention of cardiovascular risk factors; these 
include blood pressure control, dyslipidemia treatment, smoking cessation and aspirin therapy. 
Importantly, improved glycemic control has been shown to reduce the risk of cardiovascular 
events (Mealey & Ocampo 2007).   
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Chronic microvascular complications of diabetes mellitus 
Nephropathy 
Diabetic nephropathy occurs in 20–40% of patients with DM and is the leading cause of end-
stage renal disease (Mealey & Ocampo 2007). The earliest clinical evidence of nephropathy 
is the appearance of low but abnormal levels (30 mg/day or 20 μg/min) of albumin in the 
urine (Gross et al. 2005). With progression of the disease, large amounts of protein excreted 
in the urine (proteinuria) and renal hypertension, may then progress to end-stage renal disease. 
Retinopathy 
Diabetic retinopathy is characterized by vascular closure, and proliferative diabetic 
retinopathy, characterized by the growth of new blood vessels on the retina and posterior 
surface of the vitreous (Bloomgarden 2004). Glycemic control and blood pressure control 
can prevent and delay the progression of diabetic retinopathy in patients with diabetes 
(Higgins et al. 2007).  
 
Neuropathy 
Neuropathy is a common complication of both type 1 and type 2 DM, with predominantly 
small-fiber involvement beginning at the distal extremities and progressively becoming more 
proximal with time and duration of DM. ‘Burning’ or ‘prickly’ feet are common descriptions 
from diabetic neuropathy patients. Recognition of neuropathy is very important because it 
represents an independent risk factor for ulcers of the skin and amputations. Diabetic 
neuropathy causes loss of protective sensation and alteration of biomechanics, which are 
associated with the increased risk of limb amputation (Kelkar 2005). 
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2.5 Oral complications of diabetes mellitus. 
 
Periodontal diseases 
  
DM is considered as a risk factor for development of periodontal disease. The glycemic 
control is an important factor which affects the prevalence and severity of periodontal disease. 
The duration of DM appears to affect the severity of periodontal disease.  
Several factors have been proposed to explain the increased susceptibility to periodontal 
diseases in diabetics, including alteration in subgingival microflora, alteration in host response 
and altered wound healing (Ryan et al. 2003). 
 
Salivary dysfunction & xerostomia 
Patients with uncontrolled diabetes are susceptible to salivary disorders. Reduced salivary 
flow rate may be due to dehydration caused by polyurea or to alterations in the basement 
membrane of salivary glands. In addition people with DM often take medication not only for 
DM but for other related systemic conditions. These medications may have significant 
xerostomic effect (Vernillo 2003).   
 
 
 
 
 
 12
 
 
Dental caries 
An increase in the rate of dental caries may be related to salivary dysfunction. In addition 
patients with hyperglycemia present high glucose levels in gingival crevicular fluid (GCF) 
which could increase their risk of developing new and recurrent dental caries. Regular dental 
visits and caries prevention programs with fluoride supplement is important for these patients 
(Vernillo 2003, Nauntofte et al. 2003).
  
Figure 1. Salivary hypofunction, xerostomia and dental caries in diabetic patient (Ship 
2003).  
 
Oral mucosal diseases.  
DM is associated with a greater likelihood of developing certain oral mucosal disorders. There 
are reports of greater prevalence of lichen planus, recurrent aphthous stomatitis, and oral 
fungal infections. While these associations have not been found consistently in all populations 
of subjects with DM, they may be due to alterations in immune responsiveness (Ship 2003).   
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Figure 2. Oral reticular lichen planus in a patient with type 2 diabetes (Ship 2003).  
 
Candidiasis 
Another manifestation of DM and an oral sign of systemic immunosuppression is the presence 
of opportunistic infections, such as oral candidiasis. Several factors like poor glycemic control, 
xerostomia and wearing dentures, are associated with the development of candidiasis in 
diabetic patients. This may be superimposed with cigarette smoking and insufficient oral 
hygiene. The oral health care professional can readily make the diagnosis of oral candidiasis 
and provide therapy. Most importantly, the dentist should pursue the infection’s aetiology. 
This may help in the detection of undiagnosed patients with DM (Ship 2003).
 
Figure 3. Oral pseudomembraneous candidiasis in a patient with poorly controlled type 
1 diabetes (Ship 2003).
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Burning mouth syndrome  
Patients with burning mouth or burning tongue syndrome usually exhibit no clinically 
detectable lesions, although the symptoms of pain and burning can be intense. Etiologic 
factors can include salivary dysfunction, candidiasis and neuropathy of autonomic and sensory 
nerves in the oral cavity. The prevalence of neuropathy is increasing with the progression of 
DM. Neuropathy may lead to oral symptoms of paresthesia and tingling, numbness, burning 
or pain caused by pathological changes involving the nerves in the oral region (Vernillo 
2003).
 
 
3.0 Periodontal diseases 
Periodontal disease is a multifactorial disease that has been associated with multiple risk 
factors. These disorders are triggered by the accumulation of dental plaque. The clinical signs 
are caused by the resultant inflammatory and immune responses. There are two main 
diagnostic categories of periodontal diseases, Gingivitis and Periodontitis. 
Gingivitis is the presence of gingival inflammation which results in reversible destruction of 
the gingival tissues. Gingivitis is characterized by gingival redness, oedema, bleeding, 
changes in contour, loss of tissue adaptation to the teeth, and increased flow of GCF. 
  
Periodontitis is the presence of inflammation at sites where there has been apical migration of 
the junctional epithelium onto the root surface with concomitant loss of connective tissue and 
alveolar bone. 
Clinically, periodontitis is usually characterised by pocket formation, loss of clinical 
attachment and bleeding on probing (BOP). Suppuration and increased mobility of the tooth 
may also be present.  Radiographically it is characterised by horizontal and/or vertical bone 
loss. 
Periodontitis is a multifactorial disease; several risk factors are associated with the 
development of periodontitis: 
o Microbial risk factor:  More than 500 species have been isolated from periodontal 
pockets. It is likely that only a small percentage of these bacteria are periodontal 
pathogens. Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, 
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Prevotella intermedia, Tannerella forsythia, Fusobacterium nucleatum and 
Peptostreptococcus micros are all significant markers for destructive periodontal 
disease in adult subjects. Based on calculated odds ratios, T. forsythia and P. 
gingivalis are the strongest bacterial markers for this disease and are infrequently 
cultured from subjects without periodontal bone loss (Van Winkelhoff et al. 2002).   
o Systemic risk factors:  Certain systemic diseases may impair host defence to 
periodontal infection e.g., DM, HIV and cyclic neutropenia. 
o Genetic risk factor, gender and ethnicity.  
o Environmental risk factors: Oral hygiene, cigarette smoking, stress and oral hygiene. 
o Local risk factors: These factors likely act by promoting plaque accumulation e.g., 
anatomical, restorative, orthodontic and habits contributing factors (Greenwell et al. 
2004, Lamster 2006). 
      
 
Epidemiology 
Epidemiological studies of periodontitis show that most adults have mild to moderate 
periodontitis. A smaller group of adults have aggressive and more advanced periodontitis 
(Löe et al 1986).  
Epidemiological studies from Europe show that few individuals less than 30 years of age have 
advanced or aggressive periodontitis. The prevalence of advanced/aggressive periodontitis is 
increasing with age, about 10-15% of adult population. In Norway it was reported that 13% of 
individuals 45-54 years of age had one or several periodontal pockets of 6 mm or more 
(Aleksejuniene & Holst 2004). 
 
3.1 Classification of periodontal disease   
  
The currently accepted classification system was described in 1999. It is based on an 
infection/host paradigm. It follows the concept that plaque- induced periodontal diseases are 
infections occurring as a result of host inflammatory and immunologic responses to dental 
plaque bacteria (Workshop on the Classification of Periodontal Diseases 1999). 
1. Gingival diseases.     
o    Dental plaque –induced gingival Diseases. 
o    Nonplaque-induced gingival lesions. 
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2. Chronic periodontitis. 
o    Localized 
o Generalized 
3. Aggressive periodontitis. 
o  Localized  
o  Generalized 
4.   Periodontitis as a manifestation of Systemic Diseases. 
5.   Necrotizing periodontal diseases. 
6.   Abscesses of the periodontium. 
7.   Periodontitis associated with endodontic lesions. 
8.   Developmental or acquired deformities and conditions. 
 
 
                                 
 
The diagnostic system used at the Dental faculty in the Oslo is based on three main 
classifications: 
A: Localization. 
B: Severity. 
C: Patient’s age.  
Classification according to localization: 
1- Localized (1-7 teeth) 
2- Generalized (> 7 teeth) 
Classification according to severity: 
1- Mild: Not diagnosed as moderate or severe periodontitis.  
2- Moderate: at least 2 teeth with bone loss >1/3, but < ½ of radiographic root length or 
clinical attachment loss >3 mm, but <5 mm.  
3- Severe: at least 2 teeth with bone loss >1/2 of radiographic root length or clinical 
attachment loss > 5 mm.  
Classification according to patient’s age: 
1- young < 30 year 
2- adult >30 year  
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3.2 Pathogenesis 
 
Periodontal disease is initiated by the accumulation of microbial plaque on the tooth surface. 
The sulcular epithelial cells will come in contact with microbial enzymes, waste product and 
surface component of bacteria. The epithelial and dendritic cells are triggered by microbial 
substances to produce pro-inflammatory cytokines and other chemical mediators. These 
mediators induce an inflammatory response within the gingival tissue. Thus the gingiva 
becomes oedematous due to fluid accumulation and cell infiltration. 
  
Polymorphonuclear cells (PMNs) along with other leukocytes such as monocyte, 
macrophages, and lymphocytes are attracted to the gingival tissue by the chemotactic factors 
including microbial proteins and host factors such as the cytokine Interleukin-8 (IL-8) . The 
PMNs arrive in the gingival crevice and begin their function of phagocytising the bacteria. 
The macrophages have a useful function in the gingival crevice by phagocytising the dead 
PMNs and their harmful enzymes. This is called the scavenging function of macrophages 
which is useful in damping down the inflammation. 
 
The immune response begins when Langerhans cells within the gingival tissue phagocyte 
bacterial antigens and take it to the regional lymph nodes. In the lymph node the Langerhans 
cells present the bacterial antigen to the lymphocytes. Committed lymphocytes return to site 
of bacterial exposure (gingival tissue) where B cells transform to plasma cells which produce 
antibody, or T cells differentiate to produce cell mediated immune response. These antibodies 
will aid the PMNs in the phagocytises of bacterial pathogens in the gingival crevice. 
 
The inflammatory cell infiltrate in the gingiva needs space to begin its function. Therefore the 
structural components like fibroblasts and collagen must be lost to create physical room for 
the infiltrating leukocytes. These inflammatory cells will produce matrix degrading enzymes 
(MMP-8) leading to connective tissue destruction. Furthermore as the layers of junctional 
epithelium are broken down and the contact to the tooth is lost, the periodontal pocket is 
formed. The anaerobic environment in the periodontal pocket will invite the colonization of 
the facultative and anaerobic microorganisms.  
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As the infiltrate extend apically, the bone is resorbed to make more room for the defence cells.  
The production of Interlukin 1β (IL-1β), Tumor Necrosis Factor α (TNFα), and Prostoglandin 
2 (PGE 2) will increase in response to bacterial infection and lead to bone resorption. 
When the disease in untreated, the tissue destruction caused by the inflammatory response  
overwhelms any tissue repair and may end with deepening of the periodontal pocket, 
attachment loss, bone resorption, granulation tissue formation and tooth loss.  
(Kinane et al. 2003, Nisengard et al. 2006). 
 
 
 
Figure 4. The critical pathway of periodontitis (Lamster 2006).
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4.0 Association between Periodontitis and Diabetes mellitus 
There is a general agreement that DM is a risk factor for periodontitis. Diabetics have a 
significant higher prevalence of periodontitis compared to non-diabetics (Papapanou 1996).  
The severity of periodontitis was significantly higher in diabetic patients compared to non-
diabetic patients (Khader et al. 2006).  
Glycemic control is considered as the risk factor for the development of periodontitis in 
diabetic patients. Poorly controlled diabetics had three fold increases in risk of having 
periodontitis compared to non-diabetics. Conversely, well controlled diabetics had no 
significant increase of periodontitis (Tsai et al. 2002). Some studies show that poorly 
controlled diabetes increases the risk of progressive bone loss and attachment loss over time 
(Taylor et al. 1998). 
The duration of having diabetes is an important factor to evaluate the risk of DM on the 
development of periodontitis (Ryan et al. 2003). 
 
 
 
 
 
Diabetes Complication 
Periodontal disease progression / infection 
Pathogenic bacteria 
Poor Metabolic Control of DM 
Figur 5.  Diabetes control and periodontal disease progression (Palmer & 
Soory 2003). 
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A meta-analysis of data from a number of studies demonstrates a statistically significant 
association between type 1 DM and periodontal disease. Some studies showed more 
pronounced gingivitis in type 1 DM, but failed to detect notable differences in periodontal 
conditions between type 1 diabetics and healthy subjects (Papapanou 1996). The severity of 
periodontal disease was shown to increase with the severity of organ complications and the 
duration of DM. Type 1 diabetic patients with advanced complications had significantly more 
bleeding on probing, pockets ≥ 4 mm deep, and had more attachment loss than patients 
without complications (Karjalainen et al. 1994). 
Periodontal destruction can start very early in life in diabetic children and becomes more 
prominent as children become adolescents (Lalla et al. 2006).  
Many studies on periodontal disease in patients with type 2 DM have been conducted in the 
Pima Indians in the U.S.A. This population has the highest prevalence of DM in the world, 
with 50% of its population older than 35 years of age being diagnosed with type 2 DM. 
The diabetics in the Pima Indians population had higher prevalence and severity of 
periodontitis compared to non-diabetics of the same population. It was concluded that DM 
increases the risk of developing periodontitis by about three fold (Shlossman et al. 1990). 
Type 2 DM may also increase the risk of alveolar bone destruction over time. In a two-year 
longitudinal study was reported a fourfold increased risk of progressive alveolar bone loss in 
adults with type 2 diabetics compared with non-diabetics (Taylor et al. 1998). 
 
 
 
Figur 6. The severity of periodontal disease among diabetic and nondiabetic Pima 
Indians (http://www.diabetesmonitor.com/b285.htm). 
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4.1.0 Effect of diabetes on the periodontium 
4.1.1 Effect on microflora 
Several studies have focused on the alteration of oral microflora in diabetics. Some of these 
studies have found a relation between glycemic control and alterations in microflora which 
may increase the susceptibility of diabetics to periodontal disease. Ciantar et al. (2005) has 
found that the counts of Capnocytophaga species were significantly higher in periodontal 
pockets of diabetics compared to periodontal pockets in healthy individuals. 
Other studies did not find a significant difference in the oral microflora between diabetics and 
healthy individuals. Thorstenseon et al. (1996) studied several bacterial species in the 
subgingival microflora in long-term type 1 diabetics and non-diabetics. They reported that A. 
actinomycetumcomitans, C. rectus, Capnocytophaga species, E. corrodens, F. nucleatum, P. 
gingivalis, and P. intermedia are recovered in diabetics a well as non-diabetics. The same 
study observed that P. gingivalis was detected both in shallow and deep pockets in diabetic 
subjects, whereas the pathogen was only found in deep pockets in non-diabetic individuals. 
Local environmental changes in diabetics because of salivary alteration and high glucose 
levels in GCF may result in shifts of the microbial flora (Andersen et al. 2007). 
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The differences of the results of these studies suggest that alterations in the host response to 
existing periodontal pathogens may primarily be responsible for the more aggressive 
periodontal destruction observed in diabetics (Ryan et al. 2003).  
 
 
 
 
 
Figure 7. Mechanisms explaining the increased susceptibility to periodontitis in diabetics 
(Andersen et al. 2007). 
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4.1.2 Advanced Glycation End Products (AGEs) 
 
The sustained hyperglycemia in poorly controlled diabetics in combination with elevations of 
serum low density lipoproteins and triglycerides will induce an irreversible glycation of 
proteins like collagen and lipids to form the AGEs.  
AGEs will accumulate in tissues of diabetic patients and are thought to be a major link 
between the various diabetic complications. They may also be involved in tissue changes 
within the periodontium. Therefore, poorly controlled diabetics show higher AGEs levels and 
are more susceptible to periodontitis. The biologic effect of AGEs is mediated by the receptor 
for AGEs (RAGE) which is found on the surface of smooth muscle cells, endothelial cells, 
neurons, monocytes and macrophages (Lalla et al. 2001). 
  
 
 
 
AGEs and blood vessels  
Hyperglycemia results in increased expression of RAGE and increased interactions between 
the AGE and RAGE on endothelial cells, causing precoagulatory changes, thrombus 
formation and thickening of basement membrane of microvasculature (microangiopathy). 
Microangipathy is reported in gingival tissues from diabetic rodents and poorly controlled 
diabetics (Seppala et al. 1997, Gul & Ozsoy 2003). 
Microangiopathy results in impaired exchange of cells, oxygen, and metabolic products 
between the intra- and the extracellular compartment, ultimately affecting host response and 
tissue repair. 
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4.1.3 Effect on host response   
Polymorphoneuclear Leucocytes (PMNs) 
 
PMNs act as first-line-of-defence cells and the reduction of their function may explain the 
high susceptibility of diabetics to infection. Clinical investigations in diabetic patients and 
experimental studies in diabetic rats and mice have clearly demonstrated that the defects of 
PMNs include chemotactic, phagocytic and bactericidal activities. This defective PMNs 
function is highly related to poor glycemic control (Alba-Loureiro et al. 2007).  
GCF collagenase concentration is higher in diabetics and it is primarily derived from PMNs. 
(Sorsa et al. 1992).  
 
 
Monocytes, macrophages and cytokines  
 
Higher concentration of cytokines (IL-1β, PGE2, TNF-α) has been detected in GCF of diabetic 
patients with periodontitis compared to non-diabetic patients. The release of these cytokines 
in response to bacterial lipopolysaccharides (LPS) by monocytes was significantly higher in 
diabetics than in non-diabetics. This hyperinflammatory response is thought to be a result of 
AGE-RAGE interaction on monocytes and macrophages. This can result in the formation of a 
destructive cell phenotype with increased sensitivity to stimuli, resulting in excessive release 
of cytokines (Salvi et al. 1998). AGE-RAGE binding on macrophage surfaces may alter 
macrophage phenotype. This may be responsible for dysregulation of macrophages cytokine 
production and increased inflammatory tissue destruction and alveolar bone loss. It may alter 
the scavenging function of macrophages and delay the wound healing (Iacopino 1995). 
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4.1.4 Effect on collagen metabolism 
 
Collagen is the major structural protein in the periodontium and it is synthesized by gingival 
fibroblasts.  
Collagen synthesis is reduced in diabetic patients compared to non-diabetics. The formation 
of AGE in the gingival tissue may alter the cellular function in gingival tissue due to oxidative 
stress (Schmidt et al. 1996). Gingival fibroblasts produce decreased amount of collagen and 
glycosaminoglycans in hyperglycemic conditions.  
Elevated collagenase levels in gingival tissues of diabetics will increase the degradation of 
collagen in the periodontium. Therefore the homeostasis between tissue destruction and tissue 
formation is altered in diabetics. The increase in tissue destruction by collagenases and the 
decrease in collagen formation by fibroblasts will lead to more tissue destruction and 
progression of periodontitis. 
AGE formation on collagen results in increasing the cross-linking between collagen 
molecules and decreasing its solubility. The result of these changes in collagen metabolism is 
an alteration in normal homeostatic collagen turnover (Mealey & Oates 2006).   
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4.1.5 Effect on wound healing and treatment response 
Several factors are thought to be responsible for the altered wound healing in diabetics. 
o Gingival microangiopathy due to thickening of the capillary basement membrane in 
the hyperglycaemic environment can impair oxygen diffusion, metabolic waste 
elimination, PMN migration and diffusion of antibodies. 
o Reduction of collagen synthesis by fibroblasts. 
o Increased collagen degradation due to increased collagenase activity in diabetics. 
o Glycolysation of existing collagen at wound margins. 
o Defective remodelling and rapid degradation of newly synthesized, poorly cross-
linked collagen. 
      (Palmer & Soory 2003) 
The mitogenic activity of platelets in diabetics has been found to be decreased. These 
defective platelets have diminished ability to induce fibroblast proliferation than did platelets 
of non-diabetics. This may be associated with altered wound healing in diabetics (Caenazzo 
et al. 1991). 
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Figure 8. Effect of Diabetes mellitus on the host response (Palmer & Soory 2003). 
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4.2 Influence of periodontitis on diabetic status 
The inflammatory nature of periodontitis may alter the glycemic control in a similar manner 
to obesity and other inflammatory conditions. Studies have shown that diabetic patients with 
periodontal infection have a greater risk of worsening glycemic control over time compared to 
diabetic subjects without periodontitis (Taylor et al. 1996). Some studies suggest that 
periodontal disease may be a significant risk factor for myocardial infarction and stroke in 
diabetics. A recent longitudinal trial examined the effect of periodontal disease on mortality 
from multiple causes in over 600 subjects with type 2 DM in the Pima Indians population 
(Saremi et al. 2005). In subjects with severe periodontitis, the death rate from ischemic heart 
disease was 2.3 times higher than the rate in subjects with no periodontitis or only slight 
disease, when adjusted for other known risk factors. The death rate from diabetic nephropathy 
was 8.5 times higher in those subjects with severe periodontitis. The overall mortality rate 
from cardio-renal disease was 3.5-fold higher in subjects with severe periodontitis, suggesting 
that the presence of periodontal disease poses a risk for cardiovascular and renal mortality in 
people with diabetes. 
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The following biologic mechanisms have been proposed to explain how periodontitis may 
affect the systemic environment: entrance of bacteria or bacterial products, such as LPSs, 
from the ulcerated periodontal pocket into the systemic circulation and/or systemic effects of 
inflammatory mediators like TNF-α, IL-1β, and IL-6 produced locally in response to 
periodontal infection. These mediators potentially can increase low-grade inflammation and 
worsen insulin resistance (Li et al. 2000, Grossi 2001). 
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 Figure 9. Potential mechanisms for the influence of periodontitis on the diabetic status   
(Andersen et al. 2007). 
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Many mechanisms may account for the metabolic effect of TNF-α, including downregulation 
of genes related to normal insulin action and direct effects on insulin signalling, glucose 
transport, and pancreatic β cells (Grimble 2002).  
IL-6 was reported to modulate production of TNF-α and has been associated with insulin 
resistance; IL-1β in turn, seems to participate in the regulation of glucose uptake (Fernandez-
Real & Ricart 2003). 
 
Thus, these mediators have detrimental effects on glucose metabolism. Patients with diabetes 
and periodontitis have enhanced production of inflammatory mediators in the gingival tissues 
compared to non-diabetics (Salvi et al. 1998).  
In support of this observation, periodontitis superimposed on diabetes in rats resulted in 
enhanced IL-1β in fat tissue and impaired glucose tolerance (Andersen et al 2006). 
In contrast, some human and rodent studies did not find alterations in cytokine expression 
when periodontitis was superimposed on diabetics (Takeda et al. 2006). 
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5.0 Periodontal treatment and glycemic control 
The periodontal treatment of diabetic patients depends on glycemic control. In general, 
patients with well-controlled type 1 or type 2 diabetes may have no more significant risk of 
experiencing oral disease progression than do those without diabetes and hence, can be treated 
similarly. 
The response to therapy may not be as favourable in patients with poor glycemic control 
(HBA1c >10%) as it is in those with better control (HBA1c <8%). In poorly controlled 
diabetic patients, the dentist should provide proper periodontal treatment. If an infection is 
associated with systemic signs or symptoms such as increased temperature or 
lymphadenopathy, a systemic antibiotic treatment also may be indicated. A systemic 
antibiotic treatment such as Doxycyclin (100 mg/day for 14 days), used in combination with 
scaling and root planning, may help improve the glycemic control (Grossi 2001, Rees & 
Mealey 2004). 
 
Only when glycemic control has improved, should further periodontal therapy such as 
surgical care, be considered. Otherwise, the response to the treatment may be less favourable 
(Rees & Mealey 2004). 
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Figure 10. Pathway of periodontal therapy for patients with diabetes (Rees & Mealey 
2004).  
A meta-analysis of 10 intervention studies was performed in order to quantify the effects of 
periodontal treatment on HbA1c level among diabetic patients. Three investigators extracted 
data regarding intervention, outcomes, and effect size. A total of 456 patients were included in 
this analysis, with periodontal treatment as predictor and the actual change in hemoglobin A1c 
level as the outcome. The weighted average decrease in actual HbA1c level was 0.38% for all 
studies, 0.66% when restricted to type 2 diabetic patients, and 0.71% if antibiotics were given 
to them. However, none was statistically significant (Janket et al. 2005).  
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6.0 Diabetic patients in dental office  
Diabetes mellitus affects people of all ages, and its prevalence has been increasing. 
Epidemiological studies show that half of the patients with type 2 diabetes are undiagnosed. 
Patients with undiagnosed diabetes may have several intraoral signs like multiple periodontal 
abscesses, exophytic tissue extending from periodontal pocket, mobile teeth and severe bone 
loss. If the dentist suspects that a patient has undiagnosed diabetes, the patient should be 
asked about the cardinal signs and symptoms of diabetes (poydipsia “excessive thirst”, 
polyurea “excessive urination”, and polyphagia “excessive hunger, often with unexplained 
weight loss”). These patients should be referred to physician for consultation. 
Patients with diagnosed diabetes will be identified by history.  A thorough registration of their 
medical history is needed; including 
• Type of diabetes (type 1, type 2), How long the patient have had diabetes? 
• Type of medical treatment (oral hypoglycaemic agents, insulin, diet). 
• Glycemic control. Fasting blood glucose and HbA1c with regular medical updates. 
• Systemic complications resulting from diabetes, (e.g., hypertension, cardiovascular 
disease, etc.). The dentist may consult the patient’s physician to discuss modifications 
to the treatment plan, particularly when surgical procedures are anticipated.  
• Acute complications, e.g., hypoglycaemic episodes, frequency and severity. 
Dentists must educate patients and their physicians about the interrelationship between oral 
health and diabetes mellitus. 
Morning appointments are advisable since endogenous cortisol levels are generally higher at 
this time (cortisol increases blood sugar levels); makes them more tolerable for stress initiated 
from dental treatment. It is important that the diabetic patients eat their breakfast and take 
their medications before the appointment. Stress reduction and adequate pain control also are 
important during and after dental treatment. 
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Any patient with diabetes who is going to receive extensive periodontal or oral surgery 
procedures should be given dietary instructions after surgery. It is important that the total 
caloric content of the diet remain the same so that proper glycemic control of the diabetes is 
maintained. 
 
Patient’s physician should also be consulted about dosage modifications of medications in 
case of longstanding treatment session. E.g. patients with type 1 can reduce insulin dose 
before appointment while patients with type-2 can reduce oral antihyperglycemic medications. 
This is important in order to reduce the risk of hypoglycaemia under the operation. 
Hypoglycemia is the most common diabetic complication encountered in the dental office. It 
is common in patients treated with insulin and some oral hypoglycemic agents like 
sulfonylurease. In fact all diabetic patients have the risk of developing hypoglycaemia 
associated with dental treatment because off stress, pain, and imbalance between dietary 
intake and medication. The most common cause is that patients take their normal medications 
and eliminate or reduce a meal before the appointment. It is advisable to instruct the diabetic 
patients to bring their glucometers to the dental office. Before treatment, patients can assess 
their blood glucose in a matter of seconds. If the blood glucose level is at or near the lower 
limits (about 70 - 90 mg/dl), they can be given carbohydrates orally to prevent peroperative 
hypoglycaemia.  
Signs and symptoms of hypoglycaemia are most common when blood glucose levels decrease 
to less than 60 mg/dl. The first set of symptoms are called neuro-genic (or sympathetic) 
because they relate to the nervous system's response to hypoglycemia. Patients may 
experience any of the following: nervousness, sweating, intense hunger, trembling, weakness, 
palpitation and often have trouble speaking. When blood glucose levels decreased beyond 45 
mg/dl range, the brain is not getting enough glucose. At this point, symptoms progress to 
confusion, drowsiness, behaviour changes, unconsciousness and seizure. 
http://www.medicinenet.com/hypoglycemia/page2.htm. 
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Treatment of a hypoglycemic event aims to elevate glucose levels to the point where signs 
and symptoms are resolved and glucose levels return to normal. If the dentist suspects that the 
patient is experiencing a hypoglycemic episode, the treatment should be stopped. Immediately 
administer 15–20 g of fast-acting oral carbohydrate such as glucose tablets or gel, sugar, 
candy, soft drinks or juice. If the patient is unable to swallow or looses consciousness, the 
dentist should seek medical assistance.The drug of choice is 1 mg glucagon because it can 
also be given intramuscularly or subcutaneously. Glucagon causes immediate release of 
stored glucose from the liver into the blood stream. Normally the patient should respond 
within 10 min. When the patient is conscious, carbohydrate should be given orally to avoid 
reoccurrence of hypoglycemia. If the patient is not responding to glucagon treatment, then 
intravenous glucose should be given (Felleskatalogen 2007).  
Patients with sustained hyperglycemia may develope diabetic coma in the dental office but it 
is very rare. It may be difficult for the dentist to differentiate between hyper and 
hypoglycemic attacks. One should always suspect hypoglycemia and begin with oral 
carbohydrates.  
 (Vernillo 2003, Rees & Mealey 2004, Mealey et al. 2006) 
 
 
 
     Summary: 
• Good medical history including medications, regimen and the degree of glycemic 
control for diabetic patients. 
• Try to explain the relationship between DM and oral diseases and the adverse effect of 
poor glycemic control and smoking related to the complications of DM. 
• Avoid hypoglycaemic attack during treatment session by giving short morning 
appointments and make sure that the patient has eaten breakfast. 
• Carbohydrate source like sugar, juice, soda, etc. and glucagon injection should be 
available in the dental office when treating a diabetic patient.    
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 Recommendations to diabetic patients: 
• Good glycemic control. 
• Good oral hygiene. 
• Regular dental visits. 
• Consult your dentist if you get any abnormal signs and symptoms e.g., bleeding from 
gingiva, tooth mobility, abscess, etc.  
• It is recommended to follow smoke-cessation programs because of documented 
negative effect of smoking on diabetic complications. 
• When using dentures, clean thoroughly and watch possible changes in your oral soft 
tissues. 
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7.0 Conclusion: 
There is general agreement that there is a significant relationship between diabetes and 
periodontitis. Many studies have shown a high prevalence of periodontitis in diabetic patients. 
In addition a higher prevalence and more aggressive periodontitis are found in patients with 
poorly controlled diabetes. The duration of having diabetes is an important factor that affects 
the progression and severity of periodontitis.  
Alterations in the host response in diabetics to existing periodontal pathogens may be 
primarily responsible for the more aggressive periodontal destruction observed in patients 
with diabetes. Diabetes is characterized by hyperglycemia, which affects the host response by 
several mechanisms: AGE accumulation, vascular alteration, changes in oral environment due 
to increased glucose concentration in GCF resulting in shifts of the microbial flora and altered 
cell function like PMNs, fibroblasts and monocytes. These changes may lead to prolonged 
inflammation and impaired wound healing.  
Periodontitis may alter glycemic control and increase the risk of progression of diabetic 
complications and increase the mortality rate of diabetes. The mechanism behind this is the 
increasing levels of inflammatory mediator TNF-α which increase insulin resistance leading 
to poor glycemic control.  
Treatment of diabetic patient is highly dependent on the degree of glycemic control. Well 
controlled diabetics can be treated as non-diabetics, but the risk of peroperative 
hypoglycaemia should be considered. Conventional periodontal therapy combined with 
antibiotics may enhance glycemic control in poorly controlled subjects. 
Patients with previously undiagnosed type 2 diabetes may have several intraoral signs like 
multiple periodontal abscesses, exophytic tissue extending from periodontal pocket, mobile 
teeth and severe bone loss etc. The referral of these patients to the physician may help in early 
diagnosis. 
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